Nexcella moves NXC-201 into head-to-head Phase 3 test against daratumumab
The newly registered NEXICART-3 trial pits Nexcella's BCMA-directed CAR-T against a daratumumab-based regimen in untreated AL amyloidosis, a first-line setting no CAR-T has yet reached.
Executive Summary
- Nexcella has registered a Phase 3 randomized trial testing its CAR-T therapy against the current standard regimen in patients newly diagnosed with AL amyloidosis, rather than in the relapsed setting where the drug has been tested before.
- The move pushes a CAR-T therapy into first-line treatment of AL amyloidosis, a line of therapy that no cell-based competitor has yet reached, while several BCMA-targeting antibody and bispecific programs remain concentrated in later-line multiple myeloma.
- The trial's design, a randomized comparison against an active daratumumab-based regimen instead of a single-arm study, sets a higher evidentiary bar than most early cell-therapy programs in this disease attempt.
- The trial has not yet started recruiting, so the setup is entirely prospective: there is no enrollment, safety, or efficacy signal to weigh yet.
The new trial
Nexcella Inc. registered NCT07709715, titled NEXICART-3, a randomized Phase 3 study comparing NXC-201 against daratumumab combined with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in newly diagnosed systemic AL amyloidosis. The trial targets 260 patients across two arms and is registrational. It has not yet started recruiting, with a planned start date of January 2027 and a primary completion date of December 2028. NCT07709715A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL AmyloidosisNCT07709715
What it measures
The trial carries two primary endpoints: Major Organ Deterioration Progression-Free Survival (MOD-PFS), tracking time to hematologic progression, major organ deterioration, or death over 60 months, and overall complete hematologic response rate assessed at 24 months using consensus AL amyloidosis response criteria. Both measure whether NXC-201 can outperform an active standard-of-care regimen head to head, a higher bar than the single-arm designs typical of early cell-therapy testing in this disease. NCT07709715A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL AmyloidosisNCT07709715
First-line push
NXC-201 has been tested previously in relapsed AL amyloidosis under a separate Phase 1/2 study that is active and not recruiting, with a primary completion date targeted for December 2026. NEXICART-3 moves the drug into untreated, newly diagnosed patients, a line of therapy where daratumumab-based regimens are the established first-line standard and no CAR-T therapy has yet been tested in a randomized, registrational design. NCT07709715A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL AmyloidosisNCT07709715
The competitive field
CAR-T therapy is sparsely represented in AL amyloidosis: alongside NXC-201, only Alexion's dual CD19/BCMA-targeting CAR-T in relapsed or refractory disease and IASO Biotechnology's Equecabtagene Autoleucel share the modality in this indication, both still in early-phase testing. The broader competitive set in AL amyloidosis is built mostly around BCMA-targeting bispecific antibodies and antibody-drug conjugates developed for multiple myeloma, including AbbVie's etentamig and Regeneron's linvoseltamab, none of which share NXC-201's CAR-T modality. Given no CAR-T program has reached a randomized, first-line design in this disease, a result showing durable organ-protective survival that holds up against an active daratumumab comparator would be the evidence that distinguishes NXC-201 within this sparse field.
Sponsor and operational context
Nexcella runs two trials in its total portfolio, one active and not recruiting and this newly registered Phase 3 study. The trial carries a Stable protocol-stability designation with no amendments recorded since registration, consistent with a study that has not yet opened enrollment. NCT07709715A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL AmyloidosisNCT07709715
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.